Brian Barnett
Psychiatrist and Clinical Researcher
Papers
Trials
Key Impact
An active contributor to contemporary psychedelic science, Barnett has advanced clinical, epidemiological and implementation-focused work evaluating therapeutic potential, safety signals and real-world translation of psychedelic and rapid-acting treatments for mood disorders.
Background & Research
Brian S. Barnett is a psychiatrist and clinical researcher whose recent work sits at the intersection of psychedelic-assisted therapies, rapid-acting antidepressant treatments and clinical implementation science. His publications and trial involvement include clinician-survey research characterising American psychiatrists’ attitudes toward classic hallucinogens and follow-up trends over time; translational and policy-orientated reviews on psychedelic-assisted therapy; epidemiological interrogation of long-standing safety claims (for example the alleged link between psychedelic use and cancer); and case-level observations such as a report describing prolonged amelioration of mild red–green colour‑vision deficiency after psilocybin exposure. He has also participated in comparative effectiveness research, including work on ketamine versus electroconvulsive therapy (ECT) for treatment-resistant major depression.